Oppenheimer & Co’s Trueblue TBI Stock Holding History

Oppenheimer & Co’s Portfolio TBI Stock Details TBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8,845	Closed	-$256K	–	1533
2022 Q1	$256K	Buy	+8,845	New	+$243K	﹤0.01%	1267

Other funds holding TBI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

Pzena Investment Management New York $34.1B AUM 23.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Oppenheimer & Co's TBI Position: Q2 2022 in Review

Oppenheimer & Co sold out of Trueblue (TBI) in Q2 2022, closing a stake of 8,845 shares — an estimated $256K sold.

Oppenheimer & Co first reported a position in TBI in Q1 2022 and held it in 1 quarter. The position peaked at $256K in Q1 2022. 173 funds tracked by Wall St. Rank hold TBI as of Q2 2022.

Oppenheimer & Co reported no remaining Trueblue position as of Q2 2022 after selling out during the quarter.
Oppenheimer & Co sold 8,845 Trueblue shares in Q2 2022, an estimated $256K.
Oppenheimer & Co first reported a position in Trueblue in Q1 2022 and held it in 1 quarter.
Oppenheimer & Co's Trueblue position peaked at $256K in Q1 2022.
173 funds tracked by Wall St. Rank held Trueblue as of Q2 2022.

Based on Oppenheimer & Co's 13F filing for Q2 2022, filed 8 Aug 2022.